Raises $50M To Advance AI-Driven Pathology And Deliver The Future Of Precision Medicine
Summary
Pathologythe bedrock of up to 70% of clinical decisions\xb2 and a critical driver of every drug brought to marketis among the last fields of healthcare to modernize, despite mounting pressures from a workforce shortage and rising case volume. In powering drug discovery to diagnostics, Concentriq is a foundation for fueling the next novel therapies, accelerating diagnosis, and connecting a network of life sciences organizations and laboratories to match more patients with targeted treatments.We are living through an extraordinary moment in medicine, said David West, Proscias CEO. With its fast-growing customer base and strong champions of its product, it will continue to solidify its position as digital pathology moves into the mainstream.Proscia will use the capital to propel its commercial momentum, growing adoption of its platform. Building on the impact of Concentriq Embeddings, which brings foundation models to the platform and has been demonstrated to accelerate AI development by 13x, Proscia will further enable researchers and data scientists to develop and deploy algorithms for biomarker discovery, clinical trials, and companion diagnostics on its platform.Adoption of digital pathology and AI is creating an opportunity for a more connected and data-driven healthcare ecosystem, said Katie Maloney, Partner at industry-leading strategy consulting and market intelligence firm DeciBio. Its Concentriq enterprise pathology platform, precision medicine AI portfolio, and real-world data fuel the development and use of novel therapies and diagnostics to drive the fight against humanitys most challenging diseases, like cancer.